October 2020 in “The American journal of gastroenterology” This case study reports a previously undescribed cause of drug-induced autoimmune hepatitis triggered by para-aminobenzoic acid (PABA), emphasizing the need for caution with this supplement.
1 citations
,
April 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” In this case report, the authors concluded that cutaneous lupus erythematosus was induced by the PD-1 inhibitor tislelizumab during treatment for metastatic lung adenocarcinoma, despite initial remission and treatment adjustments.
January 2021 in “Pediatric Oncall” In this study, three patients with Type-1 autoimmune hepatitis experienced normalized liver enzymes and remission after six months of oral prednisolone treatment, while three others refused treatment.
1 citations
,
January 2025 in “Dermatologic Therapy” This study analyzed FAERS data to explore the risk and onset patterns of autoimmune skin diseases associated with immune checkpoint inhibitors, finding a strong association particularly with bullous pemphigoid and emphasizing the need for vigilant monitoring of these adverse effects.
May 2018 in “International Journal of Advances in Medicine” This study reports the successful management of acute liver failure in a 25-year-old woman with concurrent Hepatitis B and autoimmune hepatitis, using a combination of steroids, azathioprine, and tenofovir disoproxil fumarate.
